tradingkey.logo
搜索

Alamar Biosciences Ord Shs

ALMR
添加自选
20.590USD
+0.150+0.73%
收盘 06/01, 16:00美东报价延迟15分钟
1.42B总市值
--市盈率 TTM

Alamar Biosciences Ord Shs

20.590
+0.150+0.73%

关于 Alamar Biosciences Ord Shs 公司

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to fully automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.

Alamar Biosciences Ord Shs简介

公司代码ALMR
公司名称Alamar Biosciences Inc
上市日期Apr 17, 2026
CEOLuo (Yuling)
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址47071 Bayside Pkwy
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94538
电话15106269888
网址https://alamarbio.com
公司代码ALMR
上市日期Apr 17, 2026
CEOLuo (Yuling)

Alamar Biosciences Ord Shs公司高管

名称
名称/职务
职务
持股
持股变动
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Independent Director
Independent Director
--
--
Dr. Nicholas J. Naclerio, Ph.D.
Dr. Nicholas J. Naclerio, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ian W. Ratcliffe
Mr. Ian W. Ratcliffe
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
,
,
--
--
Mr. Yuling Luo, Ph.D.
Mr. Yuling Luo, Ph.D.
Founder, Chairman of the Board, Chief Executive Officer
Founder, Chairman of the Board, Chief Executive Officer
--
--
Mr. Timothy (Tod) White, J.D.
Mr. Timothy (Tod) White, J.D.
President
President
--
--
Mr. Shiping (Steve) Chen, Ph.D.
Mr. Shiping (Steve) Chen, Ph.D.
Founder, Chief Operating Officer, Director
Founder, Chief Operating Officer, Director
--
--
Dr. Frank R. Witney, Ph.D.
Dr. Frank R. Witney, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Justin Mcanear
Mr. Justin Mcanear
Chief Financial Officer
Chief Financial Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 4月22日 周三
更新时间: 4月22日 周三
持股股东
股东类型
持股股东
持股股东
占比
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
其他
52.83%
持股股东
持股股东
占比
Qiming Venture Partners
15.29%
Luo (Yuling Ph.D.)
9.68%
Illumina Innovation Funds
9.18%
Sherpa Healthcare Partners
6.92%
Sands Capital Ventures LLC
6.10%
其他
52.83%
股东类型
持股股东
占比
Individual Investor
17.49%
Venture Capital
15.29%
Corporation
9.18%
Investment Advisor
6.92%
Hedge Fund
6.10%
其他
45.02%

机构持股

更新时间: 4月21日 周二
更新时间: 4月21日 周二
报告期
机构数
持股数
持股占比
持股变动
2026Q2
3
19.32M
29.05%
+19.32M

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
暂无数据
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI